Sinovac Phase 3 Trial Results Expected Next Week

"); jQuery("#212 h3").html("

Related News Programmes

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1565715_1_20201217054113.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1565715-20201217.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1565715-20201217.htm', 'DCS.dcsqry', '' ); } } }); }); });

2020-12-17 HKT 05:38

Share this story

facebook

  • The government announced last week that it has secured 7.5 million doses from the mainland firm. Photo: Shutterstock

    The government announced last week that it has secured 7.5 million doses from the mainland firm. Photo: Shutterstock

Government adviser and respiratory medicine expert Dr David Hui said on Wednesday that he expected the phase 3 clinical trial results of the Sinovac coronavirus vaccine to be out on December 23.

The government announced last week that it had secured 7.5 million doses from the mainland firm as part of its procurement programme.

Dr Hui said if there were no problems with the trial results, the vaccine could be introduced here next month.

"At the moment Sinovac has published phase 1 and phase 2 data, showing the antibodies can develop in over 90 percent of the recipients," he said.

Dr Hui said that only when the company had good data would the vaccine be introduced in Hong Kong.

The government is making arrangements for three vaccines: Sinovac, Fosun BioNTech and Astrazeneca.

Dr Hui said the public wouldn't get to choose which vaccine they would get because this could lead to a shortage of one type of vaccine and a surplus of another.

He said any vaccine that was in surplus might therefore end up being wasted, as they have a shelf-life of about six months.

RECENT NEWS

HashKey Capital Partners With Tiantu AM To Explore Virtual Asset Funds

HashKey Capital has signed a memorandum of strategic collaboration with Tiantu Asset Management (Tiantu AM), a wholly o... Read more

You Can Now Make Alipay Payments With AR Glasses

RayNeo and Ant Group have announced a partnership to develop digital payment solutions for global use. The collaboratio... Read more

JICA Goes Live With Finastras Loan IQ In First Japan Deployment

Finastra has announced that the Japan International Cooperation Agency (JICA) has gone live with its Loan IQ platform. ... Read more

Japan Set To Approve First Yen-Backed Stablecoin

Japan’s Financial Services Agency (FSA) is preparing to approve the issuance of the country’s first yen-backed stab... Read more

Indonesia And China Begin Trials For Cross-Border QRIS Payments

Bank Indonesia (BI) and the People’s Bank of China (PBOC) have begun a series of trials for cross-border QR code paym... Read more

ANZ Appoints Ender Tanar As Japan Country Head

ANZ, headquartered in Melbourne, Australia, announced the appointment of Ender Tanar as Country Head for Japan, reporti... Read more